Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease
Clinical trial NCT07025226 · RECRUITING
Trial details
- NCT number
- NCT07025226
- Sponsor
- Mayo Clinic
- Status
- RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-12
- Primary completion
- 2027-09-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.